If the administration cost is lower than that of alternative drugs, it is possible to apply for adjustment to raise the upper limit of the drug. However, it should be the case where the number of companies in the formulation with the same administration route or component is one. The HIRA recently guided the pharmaceutical industry to answer questions and comparison tables before and after the change of evaluation criteria containing "change of evaluation criteria for adjusting the upper limit amount of drugs."

The evaluation criteria for this mediation application were deliberated and resolved through the Drug Reimbursement evaluation committee on the 2nd, and will be applied from September 1st.